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complete versus target-vessel revascularization.
METHODS We analyzed retrospectively 114 patients, mean age 67  12
years, 69% male, hospitalized with NSTEMI between June and
December 2012 and followed-up 12 months. Inclusion criteria were
angiographic data for signiﬁcant atherosclerotic involvement of more
than one coronary artery and proceeding to percutaneous coronary
intervention (PCI). 71 patients (62%) underwent target-vessel revas-
cularization, the rest 43 (38%) – complete revascularization.
RESULTS Demographic and clinical characteristics did not differ
signiﬁcantly between groups except for smoking (more prevalent in
target-vessel revascularization group). Procedure success was 91%in
target-vessel revascularization group and 88% in patients with com-
plete revascularization. Rate of early in-hospital complications was
not signiﬁcantly different between the groups: mortality – 2 (2.7%)
versus 1 (2.3%), periprocedural myocardial infarction – 1(1.7%) versus
1(2.3%), in target-vessel and full revascularization groups,
respectively.
During one-year follow-up combined incidence of MACE (mortality,
myocardial infarction, revascularization) was signiﬁcantly reduced
after full revascularization (4 patients, 9.3%) compared to target-
vessel intervention (12 patients, 9%), p <0.01. the difference in MACE
was driven mainly from the signiﬁcant reduction in the rate of repeat
revascularization and mortality.
CONCLUSION NSTEMI patients have improved prognosis with com-
plete versus target vessel revascularization during one-year follow-
up, without increase in the rate of in-hospital complications.TCTAP A-015
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BACKGROUND Gene polymorphisms of ABCB1, CYP2C19, PON1 and
P2Y12 may inﬂuence pharmacodynamics and clinical events of clo-
pidogrel treatment. We assessed the hypothesis that a genetic risk
score based on identiﬁed high-risk single nucleotide polymorphisms
(SNPs) would be associated with bleedings in clopidogrel-treated
Chinese STEMI patients after percutaneous coronary intervention
(PCI).
A total of 510 consecutive patients with STEMI who received an
uneventful PCI and were exposed to clopidogrel treatment for 12
months, were enrolled in the single-center registry. There were 7
high-risk SNPs selected from ABCB1 (rs1045642, rs2235047), CYP2C19
(*17), PON1 (rs662, rs854560) and P2Y12 (rs6785930, rs6809699) genes,
which were detected by the ligase detection reaction. The primary
clinical safety endpoint was the incidence of major bleeding events.
Major bleeding was quantiﬁed according to bleeding academic
research consortium deﬁnition (BARC) criteria, including type 3 and 5
in the analysis. The follow-up period was 12months.
RESULTS Overall, 46 BARC3 bleeding events (9.0%) occurred, which
included 11 (2.2%) cases of BARC 3b bleedings and 35 (6.8%) cases of
BARC 3a bleedings. After adjustment for traditional clinical risk fac-
tors, multivariate logistic regression analysis identiﬁed SNPs signiﬁ-
cantly associated with bleedings were ABCB1 (rs1045642, rs2235047)
and P2Y12 (rs6785930, rs6809699). A genetic risk score was con-
structed by summing the number of risk alleles. As a continuous
variable, the risk score resulted in an OR of 1.326 per unit increase in
score (95%CI¼1.098-1.601, p¼0.003). The addition of this genetic risk
score signiﬁcantly increased AUC from 79.3% to 82.4% (p¼0.03), and
signiﬁcantly improved the predictive ability on bleeding risk by 20%
using the NRI approach (p¼0.01).
CONCLUSION This genetic score was signiﬁcantly associated with
bleedings after PCI in our study population.
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BACKGROUND Studies indicate that soluble CD40 ligand (sCD40L) is
associated with disease progression and severity in acute coronarysyndrome (ACS), while it may provide a mechanistic link between
inﬂammation and myocardial reperfusion as well as cardiac function.
However, it is still controversial whether sequential therapy of
higher doses of atorvastatin could provide more beneﬁts in regu-
lating sCD40L, coronary blood perfusion and ventricular function
compared with a conventional dose in STEMI patients undergoing
primary PCI.
METHODS After screening, 136 STEMI patients met the inclusion
criteria and were included for analysis. All of them were divided into
three groups by using an electronic spreadsheet indicating the group
assignment by random numbers: Group A (n¼48) (received 80mg of
Atorvastatin before primary PCI, post-PCI follow-up Atorvastatin
40mg for 1 month, and Atorvastatin 20mg for 5 months); Group B
(n¼43) (received no pre-PCI loading dose of atorvastatin but did
receive Atorvastatin 40mg for 1 month and then Atorvastatin 20mg for
5 months); Group C (n¼45) (received only post-PCI Atorvastatin for
6months). TIMI ﬂow grade and Corrected TIMI Frame Count (CTFC)
after PCI would be recorded and compared among three groups. In
addition, the serum sCD40L and endothelial nitric oxide synthase
(eNOS) would be measured at admission and 1-day, 7-day, 1-month, 6-
month after PCI. Improvement of cardiac function would also be
evaluated during the follow-up.
RESULTS Patients among the three groups were well matched in de-
mographic and clinical characteristics (P>0.05). Patients in Group A
exhibited much better myocardial reperfusion indicated by CTFC
compared with Group B or Group C (no differences were observed in
TIMI ﬂow Grade 3 among three groups after PCI (P>0.05)). The levels
of sCD40L in Group A were signiﬁcantly lower than those in Group B
or Group C on 1-day and 7-day (P<0.05), but not in later sampling
points (P>0.05). Patients in Group A also gained higher levels of eNOS
and showed improvement in heart performance, with signiﬁcant in-
creases in their left ventricular ejection fraction (LVEF) (P<0.05).
Patients in Group B had relatively higher levels of eNOS as well as
signiﬁcant improvement in LVEF compared with Group C (P<0.05),
although no statistical differences were observed in sCD40L compar-
ison (P>0.05). No severe adverse reactions were observed during
study period.
CONCLUSION For STEMI patients, the sequential therapy of ator-
vastatin during primary PCI could signiﬁcantly lower serum sCD40L,
shorten CTFC and increase eNOS and LVEF. The sequential therapy of
atorvastatin treatment may reduce inﬂammatory response, improve
myocardial reperfusion and mend cardiac function with acute coro-
nary syndromes undergoing primary PCI. (ClinicalTrials.gov Identi-
ﬁer: NCT 01334671)
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BACKGROUND Recent studies of elderly patients demonstrate high
mortality from acute myocardial infarction (AMI) and increased risk
with advancing age. Although many oldest old AMI patients ( 85
years) have been treated by primary percutaneous coronary inter-
vention (pPCI) in the aging society, the prognostic importance of early
pPCI for these patients is unknown.
METHODS We evaluated consecutive 564 AMI patients (mean age
68.5 +/- 12.9, male 77%) from Mie ACS Registry in Japan from January
to December 2013. The pPCI was performed 86% patients. Patients
were divided into two groups according to the age; oldest old patients
( 85 years old: n¼62) and non-oldest old patients (< 85 years old:
n¼502). Primary end point was deﬁned as 30 days in-hospital
mortality.
RESULTS Percentage of chest pain at presentation of oldest old pa-
tients was tend to be lower than non-oldest patients (77 vs. 85%,
p¼0.13). However, there was no difference for prevalence of pPCI
between two groups, 30 days in-hospital mortality of oldest patients
was signiﬁcant higher than non-oldest patients (19.4 vs. 7%, p<0.01).
Even in the patients with pPCI, oldest patients showed poor 30 days
in-hospital mortality compared to the non-oldest patients (11.5 vs.
5.1%, p¼0.06). Only when analyzed patients with early pPCI (less
than 12 hours after onset), oldest patients showed similar favorable
prognosis to the non-oldest patients (Figure1A). However, oldest
patients with delayed pPCI(more than 12 hours) showed poor prog-
nosis compared to the non-oldest patients (Figure 1B). In
